

ABBREVIATIONS

aa	amino acid
Ab	Antibody/antibodies
ADE	Antibody Dependent Enhancement
AOX1	Alcohol oxidase 1
<i>AOX1</i>	Alcohol oxidase 1 gene
AOX2	Alcohol oxidase 2
<i>AOX2</i>	Alcohol oxidase 2 gene
ATCC	American Type Culture Collection
<i>P_{AOX1}</i>	Alcohol oxidase 1 promoter
APS	Ammonium per sulfate
BHK-21	Baby Hamster Kidney cells
BMGY	Buffered complex medium containing glycerol
BMMY	Buffered complex medium containing methanol
bp	Base pairs
CHAPS	3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate
cm	centimetre
CVD	ChimeriVax-DENV
DC	Dendritic cell
DC-SIGN	Dendritic cell-specific intercellular adhesion molecule-3-Grabbing Non-integrin
DENV	Dengue Virus
DF	Dengue fever
DHF	Dengue Hemorrhagic Fever
DMEM	Dulbecco's Modified Eagle Medium
DSS	Dengue shock syndrome
E	Envelope protein
EDIII	Envelope domain III
EDIII-T	Protein containing EDIIIs of all four serotypes linked in tandem
EDTA	Ethylenediaminetetraacetic acid
ELISA	Enzyme-linked immunosorbent assay
FCS	Fetal Calf Serum
GuHCl	Guanidine-HCl
HBcAg	Hepatitis Bcore antigen
<i>HBcAg</i>	Hepatitis B core antigen gene
HBV	Hepatitis B virus
His	Histidine
hr	hour(s)
IFN	Interferon
IgG	Immunoglobulin G
IgM	Immunoglobulin M
kDa	Kilo Dalton
kb	Kilo base pairs
L	Litre
LAV	Live attenuated virus

LB	Luria-Bertani
M	Molar
mAb	Monoclonal Antibody
μF	micro-Farad
μg	micro-gram
μl	micro-litre
μm	micro-metre
min	minute(s)
mg	milli-gram
ml	milli-litre
mM	milli-molar
mRNA	messenger RNA
ms	milli-second
MIR	Major Immunodominant Region
MOI	Multiplicity of Infection
Mut⁺	Methanol utilization plus
Mut^S	Methanol utilization slow
Mut⁻	Methanol utilization minus
N	Normal
NCR	Non-coding region
ng	nano-gram
NGC	New Guinea C
Ni-NTA	Nickel-Nitriloacetic acid
nm	nanometre
NS	Non-structural
Ω	Ohm
OD/OD₆₀₀	Optical density/ Optical density at 600nm
PAGE	Polyacrylamide gel electrophoresis
PBS	Phosphate buffered saline
PBST	Phosphate buffered saline with Tween 20
pfu	Plaque forming units
PRNT	Plaque Reduction Neutralization Test
PVP	Polyvinylpyrrolidone
rpm	Revolutions per minute
SDS	Sodium dodecyl sulphate
STAT	Signal transducers and activation of transcription
TEMED	N, N, N', N' - Tetramethylethylenediamine
TMB	3,3',5,5'-Tetramethylbenzidine
TT	Transcription termination sequence
Tyk	Tyrosine kinase
VLP	Virus-like-particle
V	Volt
WHO	World Health Organization
YF17D	Yellow Fever virus vaccine
YPDS	Yeast extract-Peptone-Dextrose-Sorbitol plates
YPD	Yeast extract-Peptone-Dextrose medium

INDEX

Introduction	1
1. Review of literature	2
1.1 Dengue	4
1.1.1 Introduction	4
1.1.2 History	4
1.1.3 Epidemiology	5
1.1.4 Entomology	6
1.1.5 Dengue transmission	7
1.1.5.1 Dengue transmission cycles	7
1.1.5.2 Human cycle of dengue virus transmission	9
1.1.6 Syndrome	10
1.1.6.1 Dengue disease classification	10
1.1.6.2 Dengue fever	11
1.1.6.3 Dengue Hemorrhagic Fever/Dengue Shock Syndrome	11
1.1.7 Primary dengue infection	12
1.1.8 Secondary dengue infection	12
1.1.9 Dengue Virus	14
1.1.9.1 Structure	14
1.1.9.2 Cellular targets of the DENV	16
1.1.9.3 Life cycle	17
1.1.9.4 Pathogenesis	19
1.1.10 Dengue vaccine candidates	21

1.1.10.1	Dengue vaccine strategies	22
1.1.10.2	Dengue vaccine candidates in clinical trials	22
1.1.10.3	Next generation dengue vaccine candidates	26
1.1.10.4	Envelope domain III-based subunit vaccine candidates	26
1.2	<i>Pichia pastoris</i> as an expression system	29
1.2.1	Emergence of <i>P.pastoris</i>	29
1.2.2	Features of <i>P. pastoris</i>	29
1.2.2.1	<i>P. pastoris</i> and other expression systems	29
1.2.2.2	Advantages of using <i>P. pastoris</i>	31
1.2.3	Strains	32
1.2.3.1	Methanol utilization phenotypes	32
1.2.3.2	<i>P. pastoris</i> KM71H	34
1.2.4	Generation of <i>P. pastoris</i> transformants	34
1.2.4.1	Cloning of gene in an integrative expression vector	35
1.2.4.2	Integration of gene into <i>P. pastoris</i> genome	36
1.2.4.3	Screening of transformed clones	36
1.3	Virus-like-particles	37
1.3.1	VLP-based vaccine strategies	37
1.3.1.1	Homologous VLP-based vaccines	37
1.3.1.2	VLPs as immune presentation platforms: Heterologous VLP-based vaccines	37
1.3.2	Immunogenicity of VLPs	37
1.4	Hepatitis B core antigen	39
1.4.1	Origin	39
1.4.2	Structural and immunological features	39

1.4.3	HBcAg as a carrier	41
2.	Aims and Objectives	44
3.	Materials and Methods	46
3.1	Materials	48
3.1.1	Yeast and bacterial strains	48
3.1.2	Source of <i>HBcAg</i> and <i>HBcAg-EDIII-2</i> genes	48
3.1.3	Expression plasmid	48
3.1.4	Virus and cell lines	49
3.1.5	Restriction endonucleases and DNA modifying enzymes	49
3.1.6	Chemicals, media components, kits and other consumables	49
3.2	Methods	52
3.2.1	Construction of recombinant plasmids	52
3.2.1.1	Generation of recombinant plasmid harbouring synthetic gene encoding HBcAg for expression in <i>P. pastoris</i>	52
3.2.1.2	Generation of recombinant plasmid harbouring synthetic gene encoding chimeric HBcAg-EDIII-2 for expression in <i>P. pastoris</i>	52
3.2.2	Preparation and transformation of competent DH5α cells	52
3.2.3	Generation of recombinant <i>P. pastoris</i> clones	53
3.2.3.1	Transformation of <i>P. pastoris</i> by electroporation	53
3.2.3.2	Screening of transformed <i>P. pastoris</i> clones	54
3.2.4	Optimization of expression	54
3.2.5	Localization of HBcAg-EDIII-2	55
3.2.6	Cultivation of <i>P. pastoris</i> at shake flask level	55
3.2.7	Purification strategy	55
3.2.7.1	Purification of HBcAg from <i>P. pastoris</i>	55

3.2.7.2	Purification of HBcAg-EDIII-2 from <i>P. pastoris</i>	56
3.2.8	Analytical methods	57
3.2.8.1	Polyacrylamide Gel Electrophoresis of proteins	57
3.2.8.2	Western Blot Analysis	58
3.2.8.3	Protein estimation	59
3.2.8.4	Ni-NTA His-sorb ELISA	59
3.2.8.5	Size exclusion chromatography	59
3.2.8.6	Electron microscopy	60
3.2.9	Immunological Characterization	60
3.2.9.1	Immunization	60
3.2.9.2	Detection of anti-EDIII-2, anti-HBcAg and anti-HBcAg-EDIII-2 antibodies	60
3.2.9.3	Competitive ELISA	61
3.2.9.4	Immunofluorescence Assay	62
3.2.9.5	Plaque Reduction Neutralization Test	63
4.	Results	65
4.1	HBcAg as a carrier for EDIII-2	66
4.2	Expression and purification of HBcAg protein from <i>P. pastoris</i>	68
4.2.1	Generation of recombinant plasmid	68
4.2.2	Intracellular expression of HBcAg in <i>P. pastoris</i>	70
4.2.3	Purification of recombinant HBcAg	71
4.2.4	Conclusions	72
4.3	Expression and purification of HBcAg-EDIII-2 protein from <i>P. pastoris</i>	73
4.3.1	Generation of recombinant plasmid	73

4.3.2	Intracellular expression of HBcAg-EDIII-2 protein in <i>P. pastoris</i>	75
4.3.3	Optimization of HBcAg-EDIII-2 expression in shake-flask cultures	76
4.3.4	Localization of HBcAg-EDIII-2	77
4.3.5	Purification of recombinant HBcAg-EDIII-2	78
4.3.6	Conclusions	80
4.4	Characterization of recombinant proteins	81
4.4.1	Size exclusion chromatography to detect the presence of higher order structures	81
4.4.2	Electron-microscopic evaluation of purified proteins for the formation of VLPs	82
4.4.3	Immunological evaluation of purified proteins	82
4.4.4	Competitive ELISA to examine the exposure of Dengue Envelope domain III on the surface of HBcAg-EDIII-2 VLPs	84
4.4.5	HBcAg-EDIII-2 elicited antibodies recognize dengue virus	85
4.4.6	Antibodies elicited by HBcAg-EDIII-2 VLPs neutralize dengue virus	85
4.4.7	Conclusions	86
5.	Discussion	87
6.	Summary	92
7.	References	95
8.	Patents and Publications	107
	Patents	107
	Publications	108
9.	Appendices	109
	Appendix-1	109
	Appendix-2	122

Introduction

Dengue is a highly endemic disease of the tropics and is rapidly spreading to the other parts of the world. It is caused by any of the four dengue virus serotypes DENV-1, -2, -3 and -4. Dengue virus belongs to flavivirus genus of flaviviridae family. There is no approved dengue vaccine candidate till now, though there are few vaccine candidates in the clinical phase of development. It is pre-requisite for a vaccine candidate to be safe for human use. Hence, non-replicating subunit vaccine candidates, which are safer than live-attenuated virus, are drawing attention in the field of dengue vaccine development.

Dengue envelope domain III is one of the most critical domains of dengue envelope protein. It is highly accessible on the virion surface and is involved in binding of the virion to the receptor on the host cell surface. This domain also contains virus neutralizing epitopes.

Virus-like-particles (VLPs), as recombinant subunit vaccines, have come into focus with the success of the VLP-based vaccines for Human Papilloma Virus and Hepatitis B Virus. Several viral structural proteins possess an intrinsic ability to assemble into non-infectious, non-replicating structures known as VLPs. VLPs mimic the structure of a virion and thus combine the advantages of whole virus vaccines, with respect to immunogenicity, and recombinant subunit vaccines, with respect to their being non-infectious and safer. One such viral protein, capable of forming VLPs, is Hepatitis B virus core antigen (HBcAg). It has been fused with a variety of antigens, from bacterial, viral and protozoan pathogens, to form chimeric VLPs.

In the present study, dengue envelope domain III has been fused to Hepatitis B core antigen, to further enhance the immunogenicity of envelope domain III. This chimeric protein was expressed in eukaryotic host *P. pastoris* and purified. The chimeric protein was able to form VLPs. It was evaluated immunologically by immunization in mice. The antiserum, so raised, was found to neutralize dengue virus.